Table 1. Clinical, histopathology and survival.
| Variable | No neoadjuvant therapy (control) (n = 13) | Three group comparison P-value | Gemcitabine-based neoadjuvant therapy (n = 14) | FOLFIRINOX neoadjuvant therapy (n = 11) | Gemcitabine vs FOLFIRINOX P-value |
|---|---|---|---|---|---|
| Gender | 0.6528 | 1.0 | |||
| Male | 4 (30.8%) | 7 (50.0%) | 6 (54.5%) | ||
| Female | 9 (69.2%) | 7 (50.0%) | 5 (45.5%) | ||
| Median age (years) | 59.2 | 0.6747 | 59.6 | 58.4 | 0.3961 |
| range | 40.1–76.7 | 45.0 – 75.1 | 42.5–71.5 | ||
| T-stage | 0.2975 | 0.2493 | |||
| pT1/ypT1 | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | ||
| pT2/ypT2 | 1 (7.7%) | 0 (0.0%) | 1 (9.1%) | ||
| pT3/ypT3 | 12 (92.3%) | 12 (85.7%) | 9 (81.8%) | ||
| pT4/ypT4 | 0 (0.0%) | 2 (14.3%) | 0 (0.0%) | ||
| Lymph node stage | 0.0782 | 0.6951 | |||
| pN0/ypN0 | 2 (15.4%) | 8 (57.1%) | 5 (45.5%) | ||
| pN1/ypN1 | 11 (84.6%) | 6 (42.9%) | 6 (54.5%) | ||
| Positive lymph node number | 0.1148 | 0.8545 | |||
| 0 | 2 (15.4%) | 8 (57.1%) | 5 (45.5%) | ||
| 1-3 | 5 (38.5%) | 5 (35.7%) | 4 (36.4%) | ||
| ≥4 | 6 (46.1%) | 1 (7.1%) | 2 (18.2%) | ||
| Metastasis stage | 0.2392 | 0.6043 | |||
| M0/ypM0 | 13 (100%) | 11 (78.6%) | 10 (90.9%) | ||
| ypM1 | 0 (0.0%) | 3 (21.4%) | 1 (9.1%) | ||
| Resection margin | 0.8076 | 0.8302 | |||
| R0 | 4 (26.7%) | 6 (42.9%) | 4 (36.4%) | ||
| R1 | 9 (73.3%) | 7 (50.0%) | 7 (63.6%) | ||
| Rx | 0 (0.0%) | 1 (7.1%) | 0 (0.0%) | ||
| UICC stage | 0.0361 | 0.5655 | |||
| UICC Ia | 0 (0.0%) | 0 (0.0%) | 1 (9.1%) | ||
| UICC Ib | 1 (7.7%) | 0 (0.0%) | 1 (9.1%) | ||
| UICC IIa | 1 (7.7%) | 6 (42.9%) | 3 (27.3%) | ||
| UICC IIb | 11 (84.6%) | 4 (28.6%) | 5 (45.5%) | ||
| UICC III | 0 (0.0%) | 1 (7.1%) | 0 (0.0%) | ||
| UICC IV | 0 (0.0%) | 3 (21.4%) | 1 (9.1%) | ||
| Survival | |||||
| Median overall | 31.6 | Log rank | 15.8 | 39.7 | Log rank |
| (months) | x22df = 6.64 | x21df = 64.26 | |||
| 95% CI | 24.5–44.5 | p = 0.0360 | 2.0–20.5 | 18.5–59.5 | p = 0.0390 |
| 2 Year (%) | 53.8 | 21.4 | 79.5 | ||
| 95% CI | 24.9–76.0 | 5.2–44.8 | 39.3–94.5 |